CEBPA and liver cancer: It has been shown that YTHDF2 targets a plethora of mRNAs for degradation in cancers, such as, TNFR2, c-Myc and CEBPA in leukemia [26, 27], EGFR, IL11, SERPINE2 and SOCS2 in liver cancer [28, 29, 39], and PD-1, CXCR4, and SOX10 in melanoma [33].